Plasmapheresis Before Rituximab in Cryoglobulinemia

Cryoglobulinemic Vasculitis Clinical Trial

Official title:
Prevention of Rituximab Related Flare by Plasmapheresis in Cryoglobulinemic Vascularitis

Status Recruiting

Clinical Trial Summary

Initial worsening following initiation of rituximab therapy in patients with cryoglobulinemic vasculitis was described in 3.6% of cases. This worsening is often a serious condition, with high levels of mortality. The objective of our study is to evaluate the efficacy of preventive plasmapheresis prior to the introduction of rituximab performed in Montpellier France since 2013 by assessing the frequency and severity of this flare effect in these patients compared to those reported in the literature.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04692363
Study type	Observational
Source	University Hospital, Montpellier
Contact	Charles HERBAUX, assistant Professor
Phone	4 67 33 83 64
Email	c-herbaux@chu-montpellier.fr
Status	Recruiting
Phase
Start date	January 1, 1999
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02593565` - Vasculitis Pregnancy Registry
Not yet recruiting	`NCT05114109` - Isatuximab in Type I Cryoglobulinemia	Phase 2
Completed	`NCT02476292` - Impact of Vasculitis on Employment and Income	N/A
Active, not recruiting	`NCT05168475` - Biologics in Refractory Vasculitis	Phase 2
Completed	`NCT03410290` - Journey of Patients With Vasculitis From First Symptom to Diagnosis